12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2024-04-26), Guardant Health's 12-1 Month Momentum % is -20.14%.
The industry rank for Guardant Health's 12-1 Month Momentum % or its related term are showing as below:
GH's 12-1 Month Momentum % is ranked worse than 53.59% of 237
companies
in the Medical Diagnostics & Research industry
Industry Median: -17.44
vs GH: -20.14
Competitive Comparison of Guardant Health's 12-1 Month Momentum %
For the Diagnostics & Research subindustry, Guardant Health's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Guardant Health's 12-1 Month Momentum % Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Guardant Health's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Guardant Health's 12-1 Month Momentum % falls into.
Guardant Health (NAS:GH) 12-1 Month Momentum % Calculation
12-1 Month Momentum % is calculated as following:
12-1 Month Momentum %
=
( Price 1-month ago
/
Price 12-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Guardant Health (NAS:GH) 12-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Guardant Health 12-1 Month Momentum % Related Terms
Thank you for viewing the detailed overview of Guardant Health's 12-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.
Guardant Health (Guardant Health) Business Description
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GH has been successfully added to your